Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

    May 26, 2023

    India as a Quad-led biomanufacturing hub

    May 25, 2023

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

      May 26, 2023

      India as a Quad-led biomanufacturing hub

      May 25, 2023

      Manappuram Finance, Rossari Biotech shares trade ex-dividend today

      May 24, 2023

      Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

      May 23, 2023

      Israeli biotech phenom puts death knell on cancer

      May 22, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»HealthMyne’s Radiomic Technology Leveraged to Identify Biomarkers That Predict Immunotherapy Treatment Responses
    Bio Technology

    HealthMyne’s Radiomic Technology Leveraged to Identify Biomarkers That Predict Immunotherapy Treatment Responses

    yourbiotechBy yourbiotechApril 7, 2022No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    HealthMyne, a pioneer in applied radiomics, declared that peer-assessed research as of late distributed in the diary Cancers has shown the capacity of its radiomics innovation to recognize biomarkers that anticipate whether patients with lung adenocarcinoma would profit from immunotherapy.

    In the Cancers article, scientists drove by Vincenza Granata assessed HealthMyne’s innovation as a quantitative imaging choice help instrument for radiomic examination of lung adenocarcinoma in chest CT filters. Scientists examined radiomic biomarkers to anticipate Overall Survival (OS) and Progression Free Survival (PFS) time.

    To play out the review, scientists chose 74 patients with histologically affirmed cellular breakdown in the lungs who went through immunotherapy and contrasted them and 50 patients with histologically affirmed lung adenocarcinoma who went through chemotherapy alone or in blend with designated treatment.

    Scientists fragmented every persistent’s sore utilizing HealthMyne’s high level imaging examination answer for extricate 573 radiometric measurements from the companion pictures to anticipate OS and PFS time. Scientists tracked down that 19 radiomic highlights were critical for anticipating OS and 108 radiomic highlights for foreseeing PFS time.

    HealthMyne's Radiomic Technology Leveraged to Identify Biomarkers That Predict Immunotherapy Treatment Responses
    To expand the worth of innovative work ventures, drug engineers need an exact and proficient method for choosing and delineating patients for clinical examinations. Various instances of friend looked into research have shown that radiomics and accuracy picture investigation recognizes biomarkers that drive more prominent personalization of treatment and gives new bits of knowledge to better choices. At HealthMyne, we endeavor to create inventive radiomic arrangements that add to the headway of this basic group of proof.
     
    – Rose Higgins, CEO, HealthMyne.
    ABOUT HEALTHMYNE
     
    HealthMyne® is a pioneer in applied radiomics, the state of the art field of extricating novel information and biomarkers from clinical pictures. Our FDA-supported and CE checked, AI-empowered arrangements permit associations to effortlessly get to and make an interpretation of weighty radiomic bits of knowledge into utilization in research, clinical results, and treatment pathways. By utilizing radiomics, our customers and accomplices can speed up the turn of events and conveyance of the most ideal medicines. HealthMyne’s methodology depends on the reason that each disease patient’s story starts with a picture. We accept that releasing the secret force of imaging information and radiomics will upset customized care – guaranteeing the right treatment without fail. Our central goal is to propel accuracy wellbeing drives through available and translatable radiomic information.
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleIpsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
    Next Article Ipsen is digging deeper into neuroscience, with a $20 million upfront charge to Exicure in a discovery deal for
    yourbiotech
    • Website

    Related Posts

    Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

    May 26, 2023

    India as a Quad-led biomanufacturing hub

    May 25, 2023

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023

    Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

    May 23, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.